Last reviewed · How we verify
NCT05311514
Allogeneic Platelet Lysate Eye Drops for the Treatment of Severe Chronic Ocular Graft-versus-host Disease
Phase 2 trial testing Allogeneic platelet lysate eye drops in Ocular Graft-versus-host Disease in 38 participants. Completed in 29 November 2024.
29 November 2024
Quick facts
| Lead sponsor | St. Petersburg State Pavlov Medical University |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 38 |
| Start date | 1 April 2021 |
| Primary completion | 29 November 2024 |
| Estimated completion | 29 November 2024 |
| Sites | 1 location across Russia |
Drugs / interventions tested
- Allogeneic platelet lysate eye drops — full drug profile →
Conditions studied
- Ocular Graft-versus-host Disease — all drugs for Ocular Graft-versus-host Disease →
Sponsor
St. Petersburg State Pavlov Medical University
Who can join
Adults 18 to 75, any sex, with Ocular Graft-versus-host Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study evaluates the efficacy and safety of allogeneic platelet lysate eye drops in patients with severe ocular graft versus host disease refractory to conventional systemic and local treatments. The corneal staining, conjunctival hyperemia, tear film break up time,Schirmer test and ocular surface disease index will be evaluated before and after allogeneic platelet lysate treatment. The safety of allogeneic platelet lysate treatment will be also assessed.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Regenerative treatment of ophthalmic diseases with stem cells: Principles, progress, and challenges.
Niu Y, Ji J, Yao K, Fu Q. · · 2024 · cited 25× · PMID 38586868 · DOI 10.1016/j.aopr.2024.02.001 -
Recent advances in ocular graft-versus-host disease.
Cheng X, Huang R, Huang S, Fan W, et al · · 2023 · cited 24× · PMID 36761771 · DOI 10.3389/fimmu.2023.1092108 -
Tackling visual impairment: emerging avenues in ophthalmology.
Lin F, Su Y, Zhao C, Akter F, et al · · 2025 · cited 4× · PMID 40357281 · DOI 10.3389/fmed.2025.1567159
Verify or expand the search:
- PubMed search for NCT05311514
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ocular Graft-versus-host Disease
Currently open trials in the same condition.
- NCT06348602 — Evaluation of Safety & Efficacy for the Prevention of Ocular GVHD With Ophthalmic Tacrolimus vs Cyclosporine in Allo-HSC · Phase 1, PHASE2 · recruiting
Other St. Petersburg State Pavlov Medical University trials
Trials by the same sponsor.
- NCT07238712 — Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies · Phase 2 · recruiting
- NCT06871007 — Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma · Phase 1, PHASE2 · enrolling by invitation
- NCT05757466 — Prolgolimab Monotherapy or in Combination With Bendamustine for r/r Classical Hodgkin Lymphoma · Phase 2 · unknown
- NCT06022952 — The Impact of the "Stone MD" Mobile App on the Prevention of Forgotten Ureteral Stents · NA · unknown
- NCT05591716 — Evaluation of the Efficacy and Safety of Unimodal Bilateral Flexible Ureteroscopy. · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05311514 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by St. Petersburg State Pavlov Medical University
- Last refreshed: 4 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05311514.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing